TY - JOUR
T1 - Microarray and FISH-based genotype-phenotype analysis of 22 Japanese patients with Wolf-Hirschhorn syndrome
AU - Shimizu, Kenji
AU - Wakui, Keiko
AU - Kosho, Tomoki
AU - Okamoto, Nobuhiko
AU - Mizuno, Seiji
AU - Itomi, Kazuya
AU - Hattori, Shigeto
AU - Nishio, Kimio
AU - Samura, Osamu
AU - Kobayashi, Yoshiyuki
AU - Kako, Yuko
AU - Arai, Takashi
AU - Oh-ishi, Tsutomu
AU - Kawame, Hiroshi
AU - Narumi, Yoko
AU - Ohashi, Hirofumi
AU - Fukushima, Yoshimitsu
PY - 2014/3
Y1 - 2014/3
N2 - Wolf-Hirschhorn syndrome (WHS) is a contiguous gene deletion syndrome of the distal 4p chromosome, characterized by craniofacial features, growth impairment, intellectual disability, and seizures. Although genotype-phenotype correlation studies have previously been published, several important issues remain to be elucidated including seizure severity. We present detailed clinical and molecular-cytogenetic findings from a microarray and fluorescence in situ hybridization (FISH)-based genotype-phenotype analysis of 22 Japanese WHS patients, the first large non-Western series. 4p deletions were terminal in 20 patients and interstitial in two, with deletion sizes ranging from 2.06 to 29.42Mb. The new Wolf-Hirschhorn syndrome critical region (WHSCR2) was deleted in all cases, and duplication of other chromosomal regions occurred in four. Complex mosaicism was identified in two cases: two different 4p terminal deletions; a simple 4p terminal deletion and an unbalanced translocation with the same 4p breakpoint. Seizures began in infancy in 33% (2/6) of cases with small (<6Mb) deletions and in 86% (12/14) of cases with larger deletions (>6Mb). Status epilepticus occurred in 17% (1/6) with small deletions and in 87% (13/15) with larger deletions. Renal hypoplasia or dysplasia and structural ocular anomalies were more prevalent in those with larger deletions. A new susceptible region for seizure occurrence is suggested between 0.76 and 1.3Mb from 4pter, encompassing CTBP1 and CPLX1, and distal to the previously-supposed candidate gene LETM1. The usefulness of bromide therapy for seizures and additional clinical features including hypercholesterolemia are also described.
AB - Wolf-Hirschhorn syndrome (WHS) is a contiguous gene deletion syndrome of the distal 4p chromosome, characterized by craniofacial features, growth impairment, intellectual disability, and seizures. Although genotype-phenotype correlation studies have previously been published, several important issues remain to be elucidated including seizure severity. We present detailed clinical and molecular-cytogenetic findings from a microarray and fluorescence in situ hybridization (FISH)-based genotype-phenotype analysis of 22 Japanese WHS patients, the first large non-Western series. 4p deletions were terminal in 20 patients and interstitial in two, with deletion sizes ranging from 2.06 to 29.42Mb. The new Wolf-Hirschhorn syndrome critical region (WHSCR2) was deleted in all cases, and duplication of other chromosomal regions occurred in four. Complex mosaicism was identified in two cases: two different 4p terminal deletions; a simple 4p terminal deletion and an unbalanced translocation with the same 4p breakpoint. Seizures began in infancy in 33% (2/6) of cases with small (<6Mb) deletions and in 86% (12/14) of cases with larger deletions (>6Mb). Status epilepticus occurred in 17% (1/6) with small deletions and in 87% (13/15) with larger deletions. Renal hypoplasia or dysplasia and structural ocular anomalies were more prevalent in those with larger deletions. A new susceptible region for seizure occurrence is suggested between 0.76 and 1.3Mb from 4pter, encompassing CTBP1 and CPLX1, and distal to the previously-supposed candidate gene LETM1. The usefulness of bromide therapy for seizures and additional clinical features including hypercholesterolemia are also described.
KW - 4p deletion
KW - Fluorescence in situ hybridization (FISH)
KW - Genotype-phenotype correlation
KW - Microarray analysis
KW - Mosaicism
KW - Seizures
KW - Wolf-Hirschhorn syndrome
UR - http://www.scopus.com/inward/record.url?scp=84894256809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894256809&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.36308
DO - 10.1002/ajmg.a.36308
M3 - Article
C2 - 24357569
AN - SCOPUS:84894256809
SN - 1552-4825
VL - 164
SP - 597
EP - 609
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 3
ER -